



CHANGE OF ADDRESS DETAILS & EXECUTIVE CHAIRMAN AGREEMENT

Sydney, 26th June 2015: Actinogen Limited (Actinogen Medical, ASX: ACW), advises that the Company has changed its address as follows:

Registered & Principal Office Address:

Level 9, Suite 901, 68 Pitt Street
SYDNEY NSW 2000

In addition, the Company advises that following a review of the performance of the Directors of the Company since completion of the acquisition of Corticrine Limited, the Board has determined that the role and duties of Mr Martin Rogers are more accurately characterised as those of an Executive, rather than a Non-Executive, Chairman. Accordingly, the Company has entered into an Executive Services Agreement with Mr Rogers taking effect from the date of his appointment as a Director of the Company on 28 November 2014.

In accordance with ASX Listing Rule 3.16.4, the material terms of the agreement with Mr Rogers are summarised as follows:

- base salary of \$80,000 per annum (exclusive of superannuation and taxes), which is consistent with the terms of Mr Rogers' initial appointment as Non-Executive Chairman, announced by the Company at the time;
- performance based bonuses from time to time at the Company's discretion; and
- notice period of 1 month.

ENDS

Actinogen Medical

Dr Bill Ketelbey

CEO & Managing Director

P: +61 2 8964 7401

E: bill.ketelbey@actinogen.com.au

 @Bill Ketelbey

About Xanamem™

Xanamem™ is being developed as a promising new therapy for Alzheimer's disease, a condition with a multi-billion dollar market potential. The cost of Alzheimer's treatment in the US alone was estimated to be US\$250bn in 2013, with this cost estimated to increase to US\$1 trillion by 2050, outstripping the cost of treating all other diseases. Alzheimer's disease is now the second leading cause of death in Australia behind ischaemic heart disease. Xanamem™'s novel mechanism of action sets it apart from existing Alzheimer's treatments. It works by blocking the production of cortisol - the stress hormone - in the hippocampus and frontal cortex, the areas of the brain most affected by Alzheimer's disease. There is growing evidence that chronic stress and elevated cortisol levels lead to changes in the brain affecting memory and to the development of amyloid plaques and neural death – the hallmarks of Alzheimer's disease.

About Actinogen Medical

Actinogen Medical is focused on the treatment of Alzheimer's disease and mild cognitive impairment, a transitional stage of cognitive impairment between normal aging and the more serious condition of Alzheimer's dementia. It is developing a novel drug to treat the condition and other age-related neurodegenerative diseases. The lead candidate drug Xanamem™, blocks the development of cortisol which appears to contribute to cognitive impairment and amyloid plaques – hallmarks of Alzheimer's disease. The Company is currently completing a second Phase I trial in healthy volunteers with results due in mid-2015 and plans to undertake a Phase II study in Alzheimer's patients in 2016.